Tislelizumab-induced hyperamylasemia: Case report and safety analysis using the FAERS database
{{output}}
Objective: To present a case report involving hyperamylasemia caused by tislelizumab and to assess the safety of tislelizumab using the FDA Adverse Event Reporting System (FAERS) database. ... ...
